Table_1_Peptidomes and Structures Illustrate How SLA-I Micropolymorphism Influences the Preference of Binding Peptide Length.xlsx
Polymorphisms can affect MHC-I binding peptide length preferences, but the mechanism remains unclear. Using a random peptide library combined with LC-MS/MS and de novo sequencing (RPLD-MS) technique, we found that two swine MHC-I molecules with high sequence homology, SLA-1*04:01 and SLA-1*13:01, had significant differences in length preference of the binding peptides. Compared with SLA-1*04:01, SLA-1*13:01 binds fewer short peptides with 8-10 amino acids, but more long peptides. A dodecapeptide peptide (RW12) can bind to both SLA-1*04:01 and SLA-1*13:01, but their crystal structures indicate that the binding modes are significantly different: the entirety of RW12 is embedded in the peptide binding groove of SLA-1*04:01, but it obviously protrudes from the peptide binding groove of SLA-1*13:01. The structural comparative analysis showed that only five differential amino acids of SLA-1*13:01 and SLA-1*04:01 were involved in the binding of RW12, and they determine the different ways of long peptides binding, which makes SLA-1*04:01 more restrictive on long peptides than SLA-1*13:01, and thus binds fewer long peptides. In addition, we found that the N terminus of RW12 extends from the groove of SLA-1*13:01, which is similar to the case previously found in SLA-1*04:01. However, this unusual peptide binding does not affect their preferences of binding peptide length. Our study will be helpful to understand the effect of polymorphisms on the length distribution of MHC-I binding peptides, and to screen SLA-I-restricted epitopes of different lengths and to design effective epitope vaccines.
History
References
- https://doi.org//10.1146/annurev-immunol-051116-052450
- https://doi.org//10.1515/hsz-2016-0305
- https://doi.org//10.1016/0022-2836%2891%2990567-p
- https://doi.org//10.1016/j.immuni.2017.02.007
- https://doi.org//10.4049/jimmunol.1501721
- https://doi.org//10.1182/blood-2012-06-437202
- https://doi.org//10.1016/s1074-7613%2801%2900091-7
- https://doi.org//10.1074/jbc.M503060200
- https://doi.org//10.1038/nsmb.3381
- https://doi.org//10.4049/jimmunol.1800611
- https://doi.org//10.7554/eLife.12556
- https://doi.org//10.1038/cmi.2017.24
- https://doi.org//10.4049/jimmunol.2001207
- https://doi.org//10.4049/jimmunol.1800914
- https://doi.org//10.4049/jimmunol.1300292
- https://doi.org//10.1038/s41467-018-07109-w
- https://doi.org//10.4049/jimmunol.1900001
- https://doi.org//10.3389/fimmu.2018.01716
- https://doi.org//10.3389/fimmu.2021.592447
- https://doi.org//10.1002/%28sici%291521-4141%28199804%2928%3A04%3C1272%3A%3Aaid-immu1272%3E3.0.co;2-e
- https://doi.org//10.4049/jimmunol.1501352
- https://doi.org//10.1016/j.immuni.2007.11.007
- https://doi.org//10.1021/acs.jproteome.7b00675
- https://doi.org//10.1073/pnas.0507386103
- https://doi.org//10.4049/jimmunol.1502062
- https://doi.org//10.1016/j.cell.2018.03.070
- https://doi.org//10.1111/j.1365-2052.2006.01459.x
- https://doi.org//10.1002/pmic.201700252
- https://doi.org//10.1038/s41592-018-0260-3
- https://doi.org//10.1073/pnas.1705691114
- https://doi.org//10.4049/jimmunol.2001165
- https://doi.org//10.4049/jimmunol.1900865
- https://doi.org//10.4049/jimmunol.2000992
- https://doi.org//10.1128/JVI.05040-11
- https://doi.org//10.1016/S0076-6879%2897%2976066-X
- https://doi.org//10.1107/s0907444906045975
- https://doi.org//10.1107/S0907444910007493
- https://doi.org//10.1107/S0907444911001314
- https://doi.org//10.1107/s0907444909052925
- https://doi.org//10.1006/jmbi.1993.1351
- https://doi.org//10.1016/j.coi.2020.05.008
- https://doi.org//10.1186/1471-2172-9-1
- https://doi.org//10.1073/pnas.94.17.8976
- https://doi.org//10.4049/jimmunol.166.2.1016
- https://doi.org//10.1016/s1074-7613%2802%2900304-7
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity